Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of Novavax Inc. NVAX rallied 7.92% to $5.86 Friday, on what proved to be an all-around great trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.06% to 16,724.46 ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares of Novavax Inc. NVAX tumbled 19.56% to $5.43 Thursday, on what proved to be an all-around dismal trading session for ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

In an emailed statement to The Fly, Novavax (NVAX) said, “As we have previously stated, we believe that our Biologics License Application for ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.